|
1
|
Ludwig J, Viggiano TR, McGill DB and Oh
BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a
hitherto unnamed disease. Mayo Clin Proc. 55:434–438.
1980.PubMed/NCBI
|
|
2
|
Andy SY and Keeffe EB: Nonalcoholic fatty
liver disease. Rev Gastrointest Disord. 2:11–19. 2002.
|
|
3
|
Angulo P and Lindor KD: Non-alcoholic
fatty liver disease Quadrennial review. J Gastroenterol Hepatol.
17:S186–S190. 2002. View Article : Google Scholar
|
|
4
|
White DL, Kanwal F and El-Serag HB:
Association between nonalcoholic fatty liver disease and risk for
hepatocellular cancer, based on systematic review. Clin
Gastroenterol Hepatol. 10:1342–1359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ikai I, Arii S, Okazaki M, Okita K, Omata
M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y,
Monden M and Kudo M: Report of the 17th Nationwide follow-up survey
of primary liver cancer in Japan. Hepatol Res. 37:676–691. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Day CP and James OF: Steatohepatitis: a
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tilg H and Moschen AR: Evolution of
inflammation in nonal-coholic fatty liver disease: the multiple
parallel hits hypothesis. Hepatology. 52:1836–1846. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Anstee QM and Goldin RD: Mouse models in
non-alcoholic fatty liver disease and steatohepatitis research. Int
J Exp Pathol. 87:1–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Denda A, Kitayama W, Kishida H, Murata N,
Tsutsumi M, Tsujiuchi T, Nakae D and Konishi Y: Development of
hepatocellular adenomas and carcinomas associated with fibrosis in
C57BL/6J male mice given a choline-deficient, L-amino acid-defined
diet. Jpn J Cancer Res. 93:125–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujii M, Shibazaki Y, Wakamatsu K, Honda
Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura
H and Yoneyama H: A murine model for non-alcoholic steatohepatitis
showing evidence of association between diabetes and hepatocellular
carcinoma. Med Mol Morphol. 46:141–152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kleiner DE, Brunt EM, Van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, Yeh M, Mccullough AJ and Sanyal AJ; Nonalcoholic
Steatohepatitis Clinical Research N. Design and validation of a
histological scoring system for nonalcoholic fatty liver disease.
Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Renehan A, Smith U and Kirkman MS: Linking
diabetes and cancer: a consensus on complexity. Lancet.
375:2201–2202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosmorduc O and Fartoux L: HCC and NASH:
how strong is the clinical demonstration? Clin Res Hepatol
Gastroenterol. 36:202–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimizu M, Tanaka T and Moriwaki H:
Obesity and hepatocellular carcinoma: targeting obesity-related
inflammation for chemo-prevention of liver carcinogenesis. Semin
Immunopathol. 35:191–202. 2013. View Article : Google Scholar
|
|
15
|
Morss AS and Edelman ER: Glucose modulates
basement membrane fibroblast growth factor-2 via alterations in
endothelial cell permeability. J Biol Chem. 282:14635–14644. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niwa Y, Matsumura M, Shiratori Y, Imamura
M, Kato N, Shiina S, Okudaira T, Ikeda Y, Inoue T and Omata M:
Quantitation of alpha-fetoprotein and albumin messenger RNA in
human hepatocellular carcinoma. Hepatology. 23:1384–1392.
1996.PubMed/NCBI
|
|
17
|
Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu
DD, Qiu LW, Yang JL, Zhang HJ, Sai WL and Chen J: Values of
circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients
with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.
12:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Satoh K, Takahashi G, Miura T, Hayakari M
and Hatayama I: Enzymatic detection of precursor cell populations
of preneoplastic foci positive for gamma-glutamyltranspeptidase in
rat liver. Int J Cancer. 115:711–716. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shin E, Ryu HS, Kim SH, Jung H, Jang JJ
and Lee K: The clinicopathological significance of heat shock
protein 70 and glutamine synthetase expression in hepatocellular
carcinoma. J Hepatobiliary Pancreat Sci. 18:544–550. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paradis V, Zalinski S, Chelbi E, Guedj N,
Degos F, Vilgrain V, Bedossa P and Belghiti J: Hepatocellular
carcinomas in patients with metabolic syndrome often develop
without significant liver fibrosis: a pathological analysis.
Hepatology. 49:851–859. 2009. View Article : Google Scholar
|
|
21
|
Wen H, Gris D, Lei Y, Jha S, Zhang L,
Huang MT, Brickey WJ and Ting JP: Fatty acid-induced NLRP3-ASC
inflammasome activation interferes with insulin signaling. Nat
Immunol. 12:408–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanada K: Serine palmitoyltransferase, a
key enzyme of sphingolipid metabolism. Biochim Biophys Acta.
1632:16–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Menaldino DS, Bushnev A, Sun A, Liotta DC,
Symolon H, Desai K, Dillehay DL, Peng Q, Wang E, Allegood J,
Trotman-Pruett S, Sullards MC and Merrill AH Jr: Sphingoid bases
and de novo ceramide synthesis: enzymes involved, pharmacology and
mechanisms of action. Pharmacol Res. 47:373–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hornemann T, Richard S, Rütti MF, Wei Y
and Von Eckardstein A: Cloning and initial characterization of a
new subunit for mammalian serine-palmitoyltransferase. J Biol Chem.
281:37275–37281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hornemann T, Wei Y and Von Eckardstein A:
Is the mammalian serine palmitoyltransferase a high-molecular-mass
complex? Biochem J. 405:157–164. 2007.PubMed/NCBI
|
|
26
|
Cinar R, Godlewski G, Liu J, Tam J,
Jourdan T, Mukhopadhya B, Harvey-White J and Kunos G: Hepatic
cannabinoid-1 receptors mediate diet-induced insulin resistance by
increasing de novo synthesis of long-chain ceramides. Hepatology.
59:143–153. 2014. View Article : Google Scholar
|
|
27
|
Ussher JR, Koves TR, Cadete VJ, Zhang L,
Jaswal JS, Swyrd SJ, Lopaschuk DG, Proctor SD, Keung W, Muoio DM
and Lopaschuk GD: Inhibition of de novo ceramide synthesis reverses
diet-induced insulin resistance and enhances whole-body oxygen
consumption. Diabetes. 59:2453–2464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lyn-Cook LE Jr, Lawton M, Tong M,
Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H and de La
Monte SM: Hepatic ceramide may mediate brain insulin resistance and
neurodegeneration in type 2 diabetes and non-alcoholic
steatohepatitis. J Alzheimers Dis. 16:715–729. 2009.PubMed/NCBI
|
|
29
|
Promrat K, Longato L, Wands JR and De La
Monte SM: Weight loss amelioration of non-alcoholic steatohepatitis
linked to shifts in hepatic ceramide expression and serum ceramide
levels. Hepatol Res. 41:754–762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kurek K, Wiesiolek-Kurek P, Piotrowska DM,
Lukaszuk B, Chabowski A and Zendzianendzian-Piotrowska M:
Inhibition of ceramide de novo synthesis with myriocin affects
lipid metabolism in the liver of rats with streptozotocin-induced
type 1 diabetes. Biomed Res Int. 2014:9808152014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee YS, Choi KM, Choi MH, Ji SY, Lee S,
Sin DM, Oh KW, Lee YM, Hong JT, Yun YP and Yoo HS: Serine
palmitoyltransferase inhibitor myriocin induces growth inhibition
of B16F10 melanoma cells through G(2)/M phase arrest. Cell Prolif.
44:320–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee YS, Choi KM, Lee S, Sin DM, Lim Y, Lee
YM, Hong JT, Yun YP and Yoo HS: Myriocin, a serine
palmitoyltransferase inhibitor, suppresses tumor growth in a murine
melanoma model by inhibiting de novo sphingolipid synthesis. Cancer
Biol Ther. 13:92–100. 2012. View Article : Google Scholar
|
|
33
|
Greenbaum CJ: Insulin resistance in type 1
diabetes. Diab Metab Res Rev. 18:192–200. 2002. View Article : Google Scholar
|
|
34
|
Bulum T, Kolaric B, Duvnjak L and Duvnjak
M: Nonalcoholic fatty liver disease markers are associated with
insulin resistance in type 1 diabetes. Dig Dis Sci. 56:3655–3663.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Regnell SE and Lernmark A: Hepatic
steatosis in type 1 diabetes. Rev Diab Stud. 8:454–467. 2011.
View Article : Google Scholar
|
